Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Apr 23, 2023

ALX Oncology Holdings (ALXO) Skyrockets +25% in April: A Deeper Dive into Earnings Results

ALX Oncology Holdings (ALXO, $6) emerged as one of the top gainers in the biotechnology sector this month, registering a remarkable 25% increase to reach $6 per share. A.I.dvisor's analysis of 965 stocks within the industry revealed that 75.24% displayed an upward trend, while 24.76% showcased a downward trend at the end of April 21, 2023. In this article, we will take a closer look at ALXO's performance, delve into its earnings results, and discuss potential investment strategies.

Bollinger Bands and Market Indicators

On April 21, 2023, ALXO broke above its upper Bollinger Band, an event typically associated with a future drop in stock prices. Bollinger Bands are a popular technical analysis tool that helps investors identify potential overbought or oversold conditions in the market. When a stock price rises above its upper band, it may signal that the stock is overbought, and investors should exercise caution.

A.I.dvisor examined 18 similar occurrences where ALXO's stock broke above its upper Bollinger Band. In 16 out of those 18 cases, the stock price experienced a subsequent decline. This historical data suggests an 89% probability of success in predicting a future drop in ALXO's stock price.

Investment Strategies and Considerations

Given the potential for a price drop following ALXO's break above its upper Bollinger Band, investors may want to consider selling the stock or exploring put options to hedge their position. Put options provide investors with the right to sell a stock at a predetermined price, offering downside protection in case the stock's price declines.

However, it is crucial to remember that past performance does not guarantee future results. Investors should conduct their own research and analysis of ALXO's financial health, growth potential, and market conditions before making any investment decisions.

ALX Oncology Holdings (ALXO) experienced a significant gain of 25% this month, positioning it as a top performer within the biotechnology industry. The stock's break above its upper Bollinger Band on April 21, 2023, might indicate a forthcoming price drop, as supported by an 89% success rate in similar past occurrences. Investors are advised to evaluate their investment strategies, considering factors such as ALXO's financial performance and market conditions, before making any decisions.

Related Ticker: ALXO

ALXO sees MACD Histogram crosses below signal line

ALXO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on May 09, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ALXO moved out of overbought territory on May 02, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on May 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ALXO as a result. In of 63 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ALXO moved below its 50-day moving average on May 24, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ALXO advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 163 cases where ALXO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALXO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.982) is normal, around the industry mean (12.488). P/E Ratio (0.000) is within average values for comparable stocks, (151.023). ALXO's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.440). Dividend Yield (0.000) settles around the average of (0.066) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (221.084).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.75B. The market cap for tickers in the group ranges from 151 to 595.57B. NONOF holds the highest valuation in this group at 595.57B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was 54%. NDTP experienced the highest price growth at 290%, while HAVLF experienced the biggest fall at -71%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -14%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 56
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
ALXODaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical stage company, which engages in the research and development of therapies for cancer patients

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
323 Allerton Avenue
Phone
+1 650 466-7125
Employees
72
Web
https://www.alxoncology.com
Ad is loading...
Discover the dynamic world of cryptocurrency trading with Tickeron's AI analysis. Capitalize on bullish and bearish patterns in Origin Protocol (OGN.X), with gains up to 27.80%. Stay ahead with Tickeron's real-time insights and make informed trading decisions. #CryptoTrading #AIAnalysis #OriginProtocol #InvestSmart
#latest#popular#patterns#artificial_intelligence#trading#technical_analysis
Dive into the world of trading excellence with our Best AI Robot of the week! In a market characterized by growth, the key to maximizing profits lies not only in mainstream large-cap stocks but also in exploring opportunities across different market segments.
This article delves into the performance of AI trading robots, specifically those utilizing the "Swing trader: Long-Short Equity Strategy (TA&FA)." These bots showcased their prowess by delivering a notable +4.98% gain while engaging in MRNA trades over the previous week. Beyond mere statistics, we explore the technical indicators and recent earnings report of MRNA to shed light on the underlying dynamics influencing the stock.
Artificial intelligence (AI) trading bots have become powerful tools for investors seeking active trading opportunities. In a recent analysis conducted on the "Day Trader: High Volatility Stocks for Active Trading (TA&FA)" platform, AI trading bots exhibited impressive performance, generating a noteworthy +4.81% gain while actively trading Shopify (SHOP) over the course of the previous week.
In the dynamic world of finance, strategic asset acquisition is a game-changer. Recently, a group of stocks within this domain has been in the spotlight, showcasing notable performances and intriguing patterns. This article delves into the recent movements of these stocks, focusing on key indicators, market capitalization, notable price events, and volume dynamics.
The Tickeron quant team is delighted to introduce our best robot of the week tailored for Trend Traders. Our sophisticated AI Robot, has been designed for manual trading enthusiasts who value independent signal selection.
Tickeron's Quant team is delighted to introduce our latest AI-powered robot designed for trading small-cap stocks, employing a distinctive fundamental stock analysis algorithm. This algorithm, renowned for its blend of in-depth analysis and intuitive signal-following capabilities, is well-suited for both novice and seasoned traders.
The Tickeron quant team proudly presents our top-performing AI robot for swing traders. This robot stands out with its remarkable accuracy, empowering traders to capitalize on diverse market conditions and transaction types. Demonstrating its proficiency, it achieved profitability in short trades during last week's strong uptrend in the US stock markets.
One such example is the "Trend Trader: Popular Stocks (TA&FA)" platform, where AI trading robots demonstrated their prowess by generating a notable gain while actively trading Adobe Inc. (ADBE) over the previous week. In this article, we delve into a technical analysis of ADBE's recent performance, shedding light on key indicators and recent earnings results.
​​​​​​​The railroads sector, encompassing prominent players such as Canadian Pacific Railway (CP), CSX Corporation (CSX), Norfolk Southern Corporation (NSC), Canadian National Railway Company (CNI), and Union Pacific Corporation (UNP), has undergone a noteworthy surge in performance over the past week. However, a closer examination reveals a complex landscape marked by negative outlook signals and fluctuating market dynamics.
The Tickeron quant team is excited to introduce our premier AI robot, specifically optimized for Swing Traders. This tool represents the pinnacle of our technological advancements in trading algorithms. Excelling in the market, it has achieved an impressive feat, earning twice as much as the S&P 500 in just the past week.
In the whirlwind of the current mergers and acquisitions frenzy, investors are reaping substantial rewards as stocks within the merger industry theme surged by an impressive 20.9% on average over the past month.
The Tickeron quant team is delighted to introduce our top-performing AI robot tailored for beginners. Our AI Robot specializes in navigating the high-tech stocks within the NASDAQ 100 index, renowned for their liquidity and moderate volatility—making them an ideal choice for novice traders.
In the dynamic landscape of the US stock markets, where unpredictability has become the norm, finding a trading strategy that not only thrives in periods of growth but also shields against sharp corrections is paramount.
The Tickeron quant team proudly introduces our premier AI Robot, tailor-made for trend traders who prefer manual trading and selecting their own signals. This AI Robot stands out with its impressive track record of consistent trading predictions, empowering traders to align their decisions with personal preferences.
Tickeron is excited to highlight the exceptional performance of our top AI robot this week, given the recent downturn in major US stock indices. While the SP500, NASDAQ 100, and Dow Jones Industrial all experienced declines, our AI robot, thanks to its well-calibrated diversification across various industries, demonstrated remarkable resilience.
As the trading week came to a close on Friday, there were notable movements across various asset classes:
Tickeron's quant team diligently monitors developed trading algorithms daily to determine the most effective ones. Today, we are delighted to present three of the best robots tailored for swing traders, showcasing consistently positive results over several months, irrespective of market conditions. This week, they underscored their efficacy by yielding impressive gains across various stocks, even as major US stock indexes dipped.
Tickeron is excited to highlight the exceptional performance of our top AI robot this week. The US stock market has experienced a consistent upward trend for the past five months, heightening the anticipation of a forthcoming correction with each passing day.
Introducing our top-performing best AI Robot of the week, designed by Tickeron's expert quant team for trading small-cap stocks. This algorithm blends classical and proprietary technical indicators, honed through advanced machine learning, to empower users with effective portfolio diversification and maximum profitability in the dynamic market.